Natera, Inc. is a U.S.-based molecular diagnostics company specializing in cell-free DNA (cfDNA) analysis. It develops and commercializes tests for oncology, women’s health, and organ health that support risk assessment, disease monitoring, and clinical decision-making.
Core products include Signatera, a personalized, tumor-informed circulating tumor DNA assay used to detect minimal residual disease and monitor cancer recurrence; Panorama, a noninvasive prenatal test; Horizon, a carrier screening panel; and Prospera, a cfDNA test for transplant rejection assessment. Natera applies next-generation sequencing and proprietary bioinformatics to analyze cfDNA from blood, and collaborates with hospitals, laboratories, and biopharma partners for clinical use, research, and companion diagnostic development.
FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
Tecentriq reduces death risk by 41% and recurrence by 36% in bladder cancer using ctDNA guidance, sparing low-risk patients from unnecessary treatment.
